论文部分内容阅读
目的 探讨血浆D-二聚体在原发性肝癌患者接受肝动脉栓塞化疗(transcatheter arterial chemoembolization, TACE)治疗后疗效及预后评价中的临床意义.方法 对接受TACE治疗的61 例原发性肝癌患者进行不同时期血浆D-二聚体浓度检测,根据实体瘤的疗效评价标准修订版(mRECIST)将TACE术疗效分为完全缓解(CR)、部分缓解(PR)、稳定(SD)、病变进展(PD),其中CR、PR、SD为病情控制组,PD为病情进展组.比较病情控制组和病情进展组TACE治疗前后血浆D-二聚体水平,分析血浆D-二聚体指标变化在TACE疗效及预后评价中的临床意义.结果 病情控制组在TACE术前后血浆D-二聚体浓度分别为122.50 μg/L、178.50 μg/L,差异无统计学意义(P＞0.05);病情进展组在TACE术前后血浆D-二聚体浓度分别为260.55 μg/L、560.50 μg/L,差异有统计学意义(P < 0.05).治疗前后病情进展组血浆D-二聚体水平均高于病情控制组,差异有统计学意义(P＜0.05).结论 血浆D-二聚体指标水平变化对TACE疗效及原发性肝癌患者预后有指导意义.“,”Objective To investigate the clinical significance of plasma D-dimer in evaluating the efficacy of transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer. Methods The plasma D-dimer concentration of 61 patients with primary hepatocellular carcinoma treated with TACE was measured at different stages. According to the revised version of mRECIST, the curative effect was divided into complete remission (CR), partial remission (PR), stable disease (SD) and progressive disease (PD). CR, PR and SD were the disease control group, and PD was the disease progression group, to compare the plasma D-dimer levels before and after TACE treatment between the disease control group and the disease progression group, and to analyze the clinical significance of the changes of plasma D-dimer indexes in the evaluation of the efficacy and prognosis of TACE. Results The plasma D-dimer concentration in the disease control group was 122.50 μg/L and 178.50 μg/L before and after TACE, respectively, with no significant difference (P＞0.05). The plasma D-dimer concentration in the disease progression group was 260.55 μg/L and 560.50 μg/L before and after TACE, respectively, with significant difference (P<0.05). The plasma D-dimer levels in the disease progression group before and after treatment were higher than those in the disease control group. There were significant differences between the two groups (P＜0.05). Conclusion The changes of plasma D-dimer level have certain guiding significance for the curative effect of TACE and the prognosis of patients with primary hepatocellular carcinoma.